Haberer Jessica E, Kidoguchi Lara, Heffron Renee, Mugo Nelly, Bukusi Elizabeth, Katabira Elly, Asiimwe Stephen, Thomas Katherine K, Celum Connie, Baeten Jared M
Massachusetts General Hospital Global Health, Boston, MA, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.
J Int AIDS Soc. 2017 Jul 25;20(1):21842. doi: 10.7448/IAS.20.1.21842.
INTRODUCTION: Adherence is essential for pre-exposure prophylaxis (PrEP) to protect against HIV acquisition, but PrEP use need not be life-long. PrEP is most efficient when its use is aligned with periods of risk - a concept termed prevention-effective adherence. The objective of this paper is to describe prevention-effective adherence and predictors of adherence within an open-label delivery project of integrated PrEP and antiretroviral therapy (ART) among HIV serodiscordant couples in Kenya and Uganda (the Partners Demonstration Project). METHODS: We offered PrEP to HIV-uninfected participants until the partner living with HIV had taken ART for ≥6 months (a strategy known as "PrEP as a bridge to ART"). The level of adherence sufficient to protect against HIV was estimated in two ways: ≥4 and ≥6 doses/week (per electronic monitoring). Risk for HIV acquisition was considered if the couple reported sex with <100% condom use before six months of ART, if they reported sex but had 100% condom use and/or six months of ART and if no sex was reported. We assessed prevention-effective adherence by cross-tabulating PrEP use with HIV risk and used multivariable regression models to assess predictors of ≥4 and ≥6 doses/week. A total of 985 HIV-uninfected participants initiated PrEP; 67% were male, median age was twenty-nine years, and 67% reported condomless sex in the month before enrolment. An average of ≥4 doses and ≥6 doses/week were taken in 81% and 67% of participant-visits, respectively. Adherence sufficient to protect against HIV acquisition was achieved in 75-88% of participant-visits with high HIV risk. The strongest predictor of achieving sufficient adherence was reporting sex with the study partner who was living with HIV; other statistically significant predictors included no concerns about daily PrEP, pregnancy or pregnancy intention, females aged >25 years, older male partners and desire for relationship success. Predictors of not achieving sufficient adherence were no longer being a couple, delayed PrEP initiation, >6 months of follow-up, ART use >6 months by the partner living with HIV and problem alcohol use. CONCLUSIONS: Over three-quarters of participant-visits by HIV-uninfected partners in serodiscordant couples achieved prevention-effective adherence with PrEP. Greater adherence was observed during months with HIV risk and the strongest predictor of achieving sufficient adherence was sexual activity.
引言:坚持服用暴露前预防药物(PrEP)对于预防感染艾滋病毒至关重要,但PrEP的使用并非需要终身进行。当PrEP的使用与风险期相匹配时最为有效——这一概念被称为预防有效依从性。本文的目的是描述在肯尼亚和乌干达的艾滋病毒血清学不一致夫妻中开展的PrEP与抗逆转录病毒疗法(ART)综合开放标签交付项目(伙伴示范项目)中的预防有效依从性及依从性预测因素。 方法:我们为未感染艾滋病毒的参与者提供PrEP,直至其感染艾滋病毒的伴侣接受抗逆转录病毒治疗≥6个月(一种被称为“PrEP作为通向抗逆转录病毒治疗的桥梁”的策略)。通过两种方式估计足以预防艾滋病毒感染的依从性水平:≥4剂/周和≥6剂/周(通过电子监测)。如果夫妻报告在抗逆转录病毒治疗6个月之前性行为时未100%使用安全套,或者报告有性行为但100%使用安全套和/或已接受抗逆转录病毒治疗6个月,以及如果报告无性行为,则被视为有感染艾滋病毒的风险。我们通过将PrEP使用情况与艾滋病毒风险进行交叉制表来评估预防有效依从性,并使用多变量回归模型来评估≥4剂/周和≥6剂/周的预测因素。共有985名未感染艾滋病毒的参与者开始服用PrEP;67%为男性,中位年龄为29岁,67%的参与者在入组前一个月报告有无保护性行为。分别有81%和67%的参与者访视中平均每周服用≥4剂和≥6剂。在75 - 88%的高艾滋病毒风险参与者访视中实现了足以预防艾滋病毒感染的依从性。实现足够依从性的最强预测因素是报告与感染艾滋病毒的研究伴侣有性行为;其他具有统计学意义的预测因素包括对每日服用PrEP、怀孕或怀孕意愿无担忧、年龄>25岁的女性、年龄较大的男性伴侣以及渴望关系成功。未实现足够依从性的预测因素包括不再是夫妻、PrEP启动延迟、随访>6个月、感染艾滋病毒的伴侣使用抗逆转录病毒治疗>6个月以及有问题的饮酒行为。 结论:在血清学不一致夫妻中,未感染艾滋病毒的伴侣超过四分之三的参与者访视实现了PrEP的预防有效依从性。在有艾滋病毒风险的月份中观察到更高的依从性,而实现足够依从性的最强预测因素是性活动。
J Acquir Immune Defic Syndr. 2017-1-1
J Acquir Immune Defic Syndr. 2017-12-15
J Acquir Immune Defic Syndr. 2020-10-1
J Acquir Immune Defic Syndr. 2018-1-1
J Acquir Immune Defic Syndr. 2023-6-1
Implement Sci Commun. 2023-1-17
J Acquir Immune Defic Syndr. 2017-1-1
J Acquir Immune Defic Syndr. 2017-1-1
J Acquir Immune Defic Syndr. 2017-1-1
Curr Opin HIV AIDS. 2016-1
N Engl J Med. 2015-12-1